CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$243.89 |
| Daily Change: | -2.11 -0.86 |
| Daily Volume: | 215,658 |
| Market Cap: | US$5.290B |
August 07, 2024 May 07, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
